<SEC-DOCUMENT>0001654954-19-010242-index.html : 20190903
<SEC-HEADER>0001654954-19-010242.hdr.sgml : 20190903
<ACCEPTANCE-DATETIME>20190903082911
ACCESSION NUMBER:		0001654954-19-010242
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190903
FILED AS OF DATE:		20190903
DATE AS OF CHANGE:		20190903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASTRAZENECA PLC
		CENTRAL INDEX KEY:			0000901832
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11960
		FILM NUMBER:		191070922

	BUSINESS ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA
		BUSINESS PHONE:		011 44 20 7304 5000

	MAIL ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZENECA GROUP PLC
		DATE OF NAME CHANGE:	19930422
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a8036k.htm
<DESCRIPTION>DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUCED BOTH THE INCIDENCE OF CARDIOVASCULAR DEATH AND THE WORSENING OF HEART FAILURE
<TEXT>
Document 1 - file: a8036k.htm

</DOCUMENT>
</SEC-DOCUMENT>